Stocks / JNJ
Johnson & Johnson's 10-K, read.
Bob rates Johnson & Johnson (JNJ) 62/100, lean bullish, on the 10-K filed February 11, 2026, updated through the 10-Q filed October 21, 2026.
JNJ operates two diversified segments (Innovative Medicine and MedTech) with strong core franchises but faces material near-term headwinds from biosimilar erosion of key immunology products (STELARA, TREMFYA), government price controls under the Inflation Reduction Act, and ongoing talc litigation. The company maintains investment-grade credit ratings and a large patent portfolio, but innovation dependency and supply-chain complexity present execution risks.
- STELARA (6.5% of 2025 sales) subject to continued biosimilar launches globally with expected revenue decline; TREMFYA (5.5% of sales) and DARZALEX (15% of sales, expiring U.S. patents in 2029) face generic/biosimilar competition.
- Inflation Reduction Act creates government-established pricing for select drugs beginning 2026 (XARELTO, STELARA, IMBRUVICA; ERLEADA added for 2028); CMS interpretation disputes pending litigation expose company to penalties.
- Significant talc litigation ongoing with potential for material settlements or judgments in excess of current accruals; company does not purchase third-party product liability insurance, relying on captive insurer with limits.
- Manufacturing complexity: 63 facilities, thousands of global suppliers; supply chain vulnerable to disruptions (regulatory action, labor disputes, natural disasters, geopolitical conflict including Russia-Ukraine war and Middle East tensions).
- Planned separation of Orthopaedics business within 18-24 months carries execution risk, significant separation costs, and uncertain realization of expected strategic and financial benefits.
Not investment advice — general research, the same for every reader. You make your own calls.
Want the full read?
Run JNJ in Bob for the live meter, or go deep with five years of filings behind it.
Read JNJ in Bob →Last read October 22, 2026. Bob's Research is a financial publisher, not an investment adviser. Everything here is general research and education — not personalized advice, and not a recommendation to buy or sell any security. Ratings are the same for every reader. You make your own calls.